Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 12/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720225 | 0.77 | GPR119 (0.44) | ACACB | |
| SCHEMBL10052757 | 0.75 | ALDH1A1 (0.35) | RXRAGRIN1GRIN2BACACBHCRTR1 | |
| SCHEMBL717550 | 0.74 | SMYD3 (0.36) | RXRAGRIN1GRIN2BACACBHCRTR1 | |
| SCHEMBL719387 | 0.74 | PDE10A (0.35) | RXRAGRIN1GRIN2BACACBHCRTR1 | |
| SCHEMBL720181 | 0.73 | PDE10A (0.37) | RXRAGRIN1GRIN2BACACBHCRTR1 | |
| SCHEMBL930098 | 0.72 | HTR1A (0.36) | ACACBMAPK1HTTKMT2AMAPT | |
| SCHEMBL15905112 | 0.71 | KMT2A (0.46) | MAPK1HTTKMT2AMAPTNPSR1 | |
| SCHEMBL942192 | 0.71 | HRH1 (0.40) | — | |
| SCHEMBL10052758 | 0.71 | ACACB (0.31) | RXRAGRIN1GRIN2BACACB | |
| SCHEMBL717505 | 0.71 | ACACB (0.33) | RXRAGRIN1GRIN2BACACBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | RXRA 1623/4885GRIN1 1031/4885GRIN2B 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.